This review addresses the detection technology used for HER2 expression and discusses novel agents for HER2-low BC, in order to evaluate dosing regimens through clinical trials and propose ideas for the diagnosis and treatment of HER2-low BC. This evidence concerns the gene ERBB2 and breast cancer.